Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsNeurocrine Biosciences launches a Phase 2 trial for NBI-1065890, targeting tardive dyskinesia with promising new treatment options.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ACTRIMS and its history!
Anti–interleukin-6 receptor therapy may offer a new treatment option for patients with NMOSD and MOGAD who do not respond to rituximab, according to new findings.
Here's some of what is coming soon to NeurologyLive® this week.
The FDA approves the FreedomEDGE infusion platform for rozanolixizumab, enhancing treatment options for generalized myasthenia gravis in clinical settings.
Janis Miyasaki, MD, MEd, FRCPC, FAAN, a pioneer in neuropalliative care, provided clinical thoughts and perspectives on National Women Physicians Day and the ways to promote women leadership within the neurology field.
In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.
1.
For older patients with Hodgkin lymphoma, novel regimens produce high response rates.
2.
iPSC-based vaccines: A new hope for preventing and treating colorectal cancer
3.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
4.
In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.
5.
High levels of traumatic stress found in caregivers of adult cancer patients
1.
Innovative Bioengineering Approaches for Erectile Function Recovery After Radical Prostatectomy
2.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
3.
AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies
4.
Decoding Efficacy, Safety, and Future Frontiers in CAR-T Cell Therapy for Hematologic Malignancies Towards CAR-T Therapy 2025
5.
A Mural of Thrombus: Unlocking the Power of Art to Combat Cardiovascular Disease
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge